Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection

Transplantation

Volumn 94, Issue 6, 2012, Pages 603-611

  Matignon, Marie ^a,b   Muthukumar, Thangamani ^a   Seshan, Surya V ^a   Suthanthiran, Manikkam ^a,b   Hartono, Choli ^a,c  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c ROGOSIN INSTITUTE   (United States)

Author keywords

Acute antibody mediated rejection; Acute T cellYmediated rejection; Graft survival; Renal transplantation

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D; CORTICOSTEROID; HLA A ANTIGEN; HLA ANTIBODY; HLA B ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CONFIDENCE INTERVAL; DISEASE CLASSIFICATION; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PLASMAPHERESIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE; T LYMPHOCYTE;

ACUTE DISEASE; ADULT; BIOPSY; CHRONIC DISEASE; COMPLEMENT C4B; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; PROTEINURIA; RISK ASSESSMENT; RISK FACTORS; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866739055     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31825def05     Document Type: Article

References (24)

1. Gailiunas P, Suthanthiran M, Busch GJ, et al. Role of humoral presensitization in human renal transplant rejection. Kidney Int 1980; 17: 63-8.
2. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibodymediated rejection workshop. Am J Transplant 2011; 11: 89-6.
3. Feucht HE, Felbert F, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 46-4.
4. Terasaki PI. A personal perspective: 100-year history of the humoral theory of transplantation. Transplantation 2012; 93: 75-1.
5. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibodymediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 46-4.
6. Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibodymediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011; 91: 121-8.
7. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 133-3.
8. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibodymediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 6-8.
9. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 83-2.
10. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 106-3.
11. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 109-9.
12. Nankivell BJ, Fenton-Lee CA, Kuypers DR, et al. Effect of histological damage on long-Term kidney transplant outcome. Transplantation 2001; 71: 51-5.
13. Rush DN, Cockfield SM, Nickerson PW, et al. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. Transplantation 2009; 88: 89-7.
14. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 139-8.
15. Everly MJ, Rebellato LM, Ozawa M, et al. Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 2010; 89: 96-2.
16. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 253-2.
17. Cooper JE, Gralla J, Cagle L, et al. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 110-3.
18. Tejani AH, Stablein DM, Sullivan EK, et al. The impact of donor source, recipient age, pre-operative immunotherapy and induction therapy on early and late acute rejections in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1998; 2: 31-8.
19. Sijpkens YW, Doxiadis II, MallatMJ, et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 2003; 75: 20-4.
20. Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 127-7.
21. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-And cell-mediated acute rejection. Transplantation 2008; 86: 175-4.
22. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitorYbased primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 27-7.
23. Waiser J, Budde K, Schütz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant 2012; 27: 124-6.
24. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 60-4.